ID   ARP-1
AC   CVCL_D523
SY   ARP1; AR-P1; ARP
DR   BTO; BTO:0003931
DR   Cosmic; 2367264
DR   GEO; GSM2774095
DR   GEO; GSM2774097
DR   GEO; GSM2774129
DR   GEO; GSM2774131
DR   GEO; GSM2774134
DR   GEO; GSM2774136
DR   Wikidata; Q54750549
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=7949178;
RX   PubMed=10936422;
RX   PubMed=14555701;
RX   PubMed=14760100;
RX   PubMed=18647998;
RX   PubMed=29045832;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Characteristics: Produces IgA kappa.
CC   Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (CelloPub=CLPUB00604).
CC   Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (CelloPub=CLPUB00604).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_XD83 ! ARD
OI   CVCL_D569 ! CAG
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 13
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   PubMed=7949178; DOI=10.1182/blood.V84.9.3063.3063;
RA   Hardin J., MacLeod S., Grigorieva I., Chang R.-X., Barlogie B.,
RA   Xiao H.-Q., Epstein J.;
RT   "Interleukin-6 prevents dexamethasone-induced myeloma cell death.";
RL   Blood 84:3063-3070(1994).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=14555701;
RA   Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D.,
RA   Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.;
RT   "Telomerase inhibition and cell growth arrest by G-quadruplex
RT   interactive agent in multiple myeloma.";
RL   Mol. Cancer Ther. 2:825-833(2003).
//
RX   PubMed=14760100; DOI=10.1158/1078-0432.CCR-0793-03;
RA   Shammas M.A., Shmookler Reis R.J., Li C., Koley H., Hurley L.H.,
RA   Anderson K.C., Munshi N.C.;
RT   "Telomerase inhibition and cell growth arrest after telomestatin
RT   treatment in multiple myeloma.";
RL   Clin. Cancer Res. 10:770-776(2004).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=29045832; DOI=10.1016/j.celrep.2017.09.078;
RA   Ezponda T., Dupere-Richer D., Will C.M., Small E.C., Varghese N.,
RA   Patel T., Nabet B., Popovic R., Oyer J., Bulic M., Zheng Y.-P.,
RA   Huang X.-X., Shah M.Y., Maji S., Riva A., Occhionorelli M., Tonon G.,
RA   Kelleher N.L., Keats J.J., Licht J.D.;
RT   "UTX/KDM6A loss enhances the malignant phenotype of multiple myeloma
RT   and sensitizes cells to EZH2 inhibition.";
RL   Cell Rep. 21:628-640(2017).
//